We believe innovation is the bedrock for meeting unmet medical needs. Innovation for us, is about finding new ways of doing things differently.

Innovation at Glenmark

Innovation is at the heart of everything we do – from discovering novel molecules, to manufacturing effective medicines to how we operate. We practice innovation by finding new ways of doing things – big or small – and strive to enrich lives across the world.

We aim to develop innovative molecules to address evolving needs of patients, in areas where we can make a real difference. Glenmark’s drug discovery endeavours are focused on the therapeutic areas of dermatology, respiratory and oncology. Our distinctive scientific capabilities have enabled us to build a strong pipeline of several first-in-class molecules - both NCEs (New Chemical Entities) and NBEs (New Biological Entities).  We have also made a mark in this area by successfully out-licensing seven of our own molecules to large multinationals.

Glenmark R&D centres are well equipped to research and develop novel molecules by combining cutting-edge technology, state-of-the-art infrastructure, and the brightest minds. Glenmark’s scientists have also invented a propriety best-in-class technology platform to manufacture bispecific antibodies, BEAT®. Glenmark’s R&D team of over 800 scientists across 5 R&D centres, in India and Switzerland, are committed to identify cures for unmet needs that matter most.